Cost of Revenue of Nabriva Therapeutics plc from 31 Dec 2019 to 30 Jun 2023

Taxonomy & unit
us-gaap: USD
Description
The aggregate cost of goods produced and sold and services rendered during the reporting period.
Summary
Nabriva Therapeutics plc quarterly and annual Cost of Revenue in USD history and change rate from 31 Dec 2019 to 30 Jun 2023.
  • Nabriva Therapeutics plc Cost of Revenue for the quarter ending 30 Jun 2023 was $9,074,000, a 104% increase year-over-year.
  • Nabriva Therapeutics plc Cost of Revenue for the twelve months ending 30 Jun 2023 was $34,277,000, a 98% increase year-over-year.
  • Nabriva Therapeutics plc annual Cost of Revenue for 2022 was $28,581,000, a 117% increase from 2021.
  • Nabriva Therapeutics plc annual Cost of Revenue for 2021 was $13,148,000, a 1616% increase from 2020.
  • Nabriva Therapeutics plc annual Cost of Revenue for 2020 was $766,000, a 994% increase from 2019.
Source SEC data
View on sec.gov
Cost of Revenue, Trailing 12 Months (USD)
Cost of Revenue, Quarterly (USD)
Cost of Revenue, YoY Quarterly Change (%)
Cost of Revenue, Annual (USD)
Cost of Revenue, YoY Annual Change (%)

Nabriva Therapeutics plc Quarterly Cost of Revenue (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q2 2023 $34,277,000 $9,074,000 +$4,619,000 +104% 01 Apr 2023 30 Jun 2023 10-Q 19 Oct 2023 2023 Q2
Q1 2023 $29,658,000 $4,438,000 +$1,077,000 +32% 01 Jan 2023 31 Mar 2023 10-Q 22 May 2023 2023 Q1
Q4 2022 $28,581,000 $16,349,000 +$11,083,000 +210% 01 Oct 2022 31 Dec 2022 10-K 17 Apr 2023 2022 FY
Q3 2022 $17,498,000 $4,416,000 +$217,000 +5.2% 01 Jul 2022 30 Sep 2022 10-Q 10 Nov 2022 2022 Q3
Q2 2022 $17,281,000 $4,455,000 +$834,000 +23% 01 Apr 2022 30 Jun 2022 10-Q 19 Oct 2023 2023 Q2
Q1 2022 $16,447,000 $3,361,000 +$3,299,000 +5321% 01 Jan 2022 31 Mar 2022 10-Q 22 May 2023 2023 Q1
Q4 2021 $13,148,000 $5,266,000 01 Oct 2021 31 Dec 2021 10-K 17 Apr 2023 2022 FY
Q3 2021 $4,199,000 +$4,174,000 +16696% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022 2022 Q3
Q2 2021 $3,621,000 01 Apr 2021 30 Jun 2021 10-Q 03 Aug 2022 2022 Q2
Q1 2021 $62,000 01 Jan 2021 31 Mar 2021 10-Q 05 May 2022 2022 Q1
Q3 2020 $25,000 01 Jul 2020 30 Sep 2020 10-Q 09 Nov 2021 2021 Q3

Nabriva Therapeutics plc Annual Cost of Revenue (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2022 $28,581,000 +$15,433,000 +117% 01 Jan 2022 31 Dec 2022 10-K 17 Apr 2023 2022 FY
2021 $13,148,000 +$12,382,000 +1616% 01 Jan 2021 31 Dec 2021 10-K 17 Apr 2023 2022 FY
2020 $766,000 +$696,000 +994% 01 Jan 2020 31 Dec 2020 10-K 17 Apr 2023 2022 FY
2019 $70,000 01 Jan 2019 31 Dec 2019 10-K 29 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.